Encouraging phase II trial for Vertex’ hepatitis drug
The study enrolled 12 treatment-naive patients with genotype 1 HCV who received VX-950 in a tablet formulation at a dose of 750mg every eight hours for 28 days
The US Food and Drug Administration (FDA) has approved two Jazz Pharmaceuticals regimens containing Ziihera (zanidatamab-hrii) for the first-line treatment of adults with unresectable, locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastroesophageal adenocarcinoma (GEA).